Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Completed · Phase 1

Conditions studied: Advanced Solid Tumors, Multiple Myeloma

In brief

For cancer cells to grow, they need to have nutrients supplied to them through blood vessels. The study drug, ACE-041, is designed to work by blocking the growth of those blood vessels and preventing cancer cells from growing. The purpose of this study is to establish safe dose levels of ACE-041 in patients with advanced solid tumors or relapsed/refractory multiple myeloma following multiple dose administration. This study will also evaluate if ACE-041 has an effect on tumors.

Key facts

Study ID

NCT00996957

Run by

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

People needed

37

Starts

2009-10-01

Expected to finish

2012-10-01

Last updated by the study team

2013-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of metastatic or unresectable advanced solid tumors (solid tumors must be measurable) or relapsed/refractory multiple myeloma for which the disease has progressed despite available standard therapies or for which no standard therapy exists.
• Life expectancy of at least 12 weeks.
• Eastern Cooperative Oncology Group (ECOG) Performance status of 0, 1, or 2 (not declining within 2 weeks prior to study day 1).

You may not qualify if…

• Central nervous system (CNS) metastases.
• Chemotherapy or other anti-cancer therapy within 4 weeks prior to study day 1, and/or nitrosoureas within the 6 weeks prior to study day 1.
• Lack of recovery from all toxic effects of previous chemotherapy, radiation therapy, biologic therapy, and/or experimental therapy with the exception of alopecia.
• Radiation therapy within 4 weeks prior to study day 1.
• Clinically significant pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal or genitourinary disease unrelated to underlying solid tumor or multiple myeloma
• Significant cardiac risk (e.g. history of myocardial infarction, unstable angina, pulmonary hypertension, clinically significant arrhythmia, congestive heart failure within 1 year prior to study day 1).
• Diagnosis or family history of hereditary hemorrhagic telangiectasia.
• Major surgery within 6 weeks prior to study day 1.
• Parenteral antibiotics, or any life-threatening or active infection requiring parenteral antibiotic therapy within 1 month prior to study day 1.
• Therapeutic anti-coagulation.
• Uncontrolled hypertension.
• Autoimmune or hereditary hemolysis.
• Clinically significant gastrointestinal bleeding or any other clinically significant active bleeding within 3 months prior to study day 1.
• Treatment with another investigational drug or device, or approved therapy for investigational use within 28 days prior to study day 1.
• Pregnancy or lactation for female patients.

Where it is running

• Acceleron Investigative Site — Scottsdale, Arizona, United States
• Acceleron Investigative Site — Durham, North Carolina, United States
• Acceleron Investigative Site — Nashville, Tennessee, United States
• Acceleron Investigative Site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.